Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

Shiqi Wang; Saowanee Wannasarit; Patricia Figueiredo; Giuseppina Molinaro; Yaping Ding; Alexandra  Correia; Luca Casettari; Ruedeekorn  Wiwattanapatapee; Jouni Hirvonen; Dongfei Liu; Wei Li; Hélder A. Santos

doi:10.1002/adtp.202000058

Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

Shiqi Wang, Saowanee Wannasarit, Patricia Figueiredo, Giuseppina Molinaro, Yaping Ding, Alexandra Correia, Luca Casettari, Ruedeekorn Wiwattanapatapee, Jouni Hirvonen, Dongfei Liu, Wei Li, Hélder A. Santos

Research output: Contribution to journal › Article › Scientific › peer-review

Abstract

In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.

Original language	English
Article number	2000058
Journal	Advanced Therapeutics
Volume	4
Issue number	1
Number of pages	11
ISSN	2366-3987
DOIs	https://doi.org/10.1002/adtp.202000058
Publication status	Published - Jan 2021
MoE publication type	A1 Journal article-refereed

Fields of Science

ANTIGEN
ENHANCEMENT
INFLAMMATION
NANOPARTICLES
PEPTIDES
POLYMERS
drug delivery
endosomal escape
macrophage phenotypes
microfluidics
polydopamine

Access to Document

10.1002/adtp.202000058

adtp.202000058Final published version, 1.74 MBLicence: CC BY-NC

Cite this

Wang, S., Wannasarit, S., Figueiredo, P., Molinaro, G., Ding, Y., Correia, A., Casettari, L., Wiwattanapatapee, R., Hirvonen, J., Liu, D., Li, W., & Santos, H. A. (2021). Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2. Advanced Therapeutics, 4(1), [2000058]. https://doi.org/10.1002/adtp.202000058

Wang, Shiqi ; Wannasarit, Saowanee ; Figueiredo, Patricia ; Molinaro, Giuseppina ; Ding, Yaping ; Correia, Alexandra ; Casettari, Luca ; Wiwattanapatapee, Ruedeekorn ; Hirvonen, Jouni ; Liu, Dongfei ; Li, Wei ; Santos, Hélder A. / Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2. In: Advanced Therapeutics. 2021 ; Vol. 4, No. 1.

@article{9aa7cd4405574d27addec14c8b9482e3,

title = "Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2",

abstract = "In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.",

keywords = "ANTIGEN, ENHANCEMENT, INFLAMMATION, NANOPARTICLES, PEPTIDES, POLYMERS, drug delivery, endosomal escape, macrophage phenotypes, microfluidics, polydopamine",

author = "Shiqi Wang and Saowanee Wannasarit and Patricia Figueiredo and Giuseppina Molinaro and Yaping Ding and Alexandra Correia and Luca Casettari and Ruedeekorn Wiwattanapatapee and Jouni Hirvonen and Dongfei Liu and Wei Li and Santos, {H{\'e}lder A.}",

year = "2021",

month = jan,

doi = "10.1002/adtp.202000058",

language = "English",

volume = "4",

journal = "Advanced Therapeutics",

issn = "2366-3987",

publisher = "Wiley-VCH",

number = "1",

}

Wang, S, Wannasarit, S, Figueiredo, P, Molinaro, G, Ding, Y, Correia, A, Casettari, L, Wiwattanapatapee, R, Hirvonen, J , Liu, D , Li, W & Santos, HA 2021, 'Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2', Advanced Therapeutics, vol. 4, no. 1, 2000058. https://doi.org/10.1002/adtp.202000058

Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2. / Wang, Shiqi; Wannasarit, Saowanee; Figueiredo, Patricia; Molinaro, Giuseppina; Ding, Yaping; Correia, Alexandra ; Casettari, Luca; Wiwattanapatapee, Ruedeekorn ; Hirvonen, Jouni ; Liu, Dongfei ; Li, Wei ; Santos, Hélder A.

In: Advanced Therapeutics, Vol. 4, No. 1, 2000058, 01.2021.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Intracellular delivery of budesonide and polydopamine co-loaded in endosomolytic poly(butyl methacrylate-co-methacrylic acid) grafted acetalated dextran for macrophage phenotype switch from M1 to M2

AU - Wang, Shiqi

AU - Wannasarit, Saowanee

AU - Figueiredo, Patricia

AU - Molinaro, Giuseppina

AU - Ding, Yaping

AU - Correia, Alexandra

AU - Casettari, Luca

AU - Wiwattanapatapee, Ruedeekorn

AU - Hirvonen, Jouni

AU - Liu, Dongfei

AU - Li, Wei

AU - Santos, Hélder A.

PY - 2021/1

Y1 - 2021/1

N2 - In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.

AB - In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.

KW - ANTIGEN

KW - ENHANCEMENT

KW - INFLAMMATION

KW - NANOPARTICLES

KW - PEPTIDES

KW - POLYMERS

KW - drug delivery

KW - endosomal escape

KW - macrophage phenotypes

KW - microfluidics

KW - polydopamine

U2 - 10.1002/adtp.202000058

DO - 10.1002/adtp.202000058

M3 - Article

VL - 4

JO - Advanced Therapeutics

JF - Advanced Therapeutics

SN - 2366-3987

IS - 1

M1 - 2000058

ER -